Amsterdam: The Council adopted the EU pharma package on 28 September 2026, completing its side of a reform that rewrites how Europe rewards new medicines. The agreement sets new periods of regulatory protection, adds a reward for developers of priority antibiotics and lets generic makers prepare for market entry earlier. It now needs adoption by the European Parliament and publication in the Official Journal before it takes effect.
The core of the EU pharma package is the balance between data protection and market protection. Companies keep exclusive rights to their pre-clinical and clinical trial data for eight years. Market protection runs for one year as a baseline and can reach two years for innovative medicines, so the maximum combined protection is eleven years, or twelve with the transferable exclusivity voucher. A medicine can earn an extra year if it meets at least two conditions linked to comparative clinical trials, trials in several member states and early application in the Union. A further year applies to products that meet an unmet medical need.
The voucher is the most closely watched new tool, because it targets antimicrobial resistance. Developers of priority antibiotics receive one additional year of market protection that they can use on a product of their choice. The Council added a blockbuster clause, which means the voucher cannot apply to a product whose annual gross sales exceeded €490 million over the preceding four years. That ceiling limits the reward to products that are not already highly profitable.
Generic and biosimilar makers gain from a broadened Bolar exemption. It allows them to carry out the studies and trials they need during the patent period, so that they can enter the market on the first day after protection ends. The exemption also covers the steps needed to take part in public procurement tenders. Earlier entry should help health systems that depend on cheaper copies to control costs. Those provisions show how the EU pharma package serves generic competition as well as innovation.
Rare disease medicines receive their own rules in the EU pharma package. Standard orphan medicines keep nine years of market exclusivity, while breakthrough orphans can earn two more years, for a maximum of eleven. The breakthrough label is reserved for treatments for conditions that had no authorised therapy in the Union and that produce a clinically meaningful reduction in disease severity or mortality.
Supply is the third strand. Member states may require companies to supply adequate quantities of protected medicines, and the text includes safeguards so that such obligations cannot be used to facilitate parallel trade. Shortages have been a recurring political problem in Europe, so this clause gives governments a legal basis to press companies when stocks run low.
The Council describes the outcome as a fairer and more competitive pharmaceutical sector. Patient groups and public payers will judge it on whether the new periods deliver faster access to medicines across all 27 countries, while industry will judge it on the strength of the incentives. The final test of the EU pharma package comes with the Parliament vote and the first products that earn the new rewards.
